Collaborative Group on Hormonal Factors in Breast Cancer (2001). Familial breast cancer: Collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet
P. Lichtenstein, N. V. Holm, P. K. Verkasalo, A. Iliadou, J. Kaprio, M. Koskenvuo, E. Pukkala, A. Skytthe, and K. Hemminki (2000). Environmental and heritable factors in the causation of cancer-Analyses of cohorts of twins from Sweden, Denmark, and Finland. N. Engl. J. Med.
J. Peto, and T. M. Mack (2000). High constant incidence in twins and other relatives of women with breast cancer. Nat. Genet.
D. T. Bishop, L. Cannon-Albright, T. McLellan, E. J. Gardner, and M. H. Skolnick (1988). Segregation and link-age analysis of nine Utah breast cancer pedigrees. Genet. Epidemiol.
J. M. Hall, M. K. Lee, B. Newman, J. E. Morrow, L. A. Anderson, B. Huey, and M. C. King (1990). Linkage of early-onset familial breast cancer to chromosome 17q21. Science
R. Wooster, S. L. Neuhausen, J. Mangion, Y. Quirk, D. Ford, N. Collins, K. Nguyen, S. Seal, T. Tran, D. Averill, P. Fields, G. Marshall, S. Narod, G. M. Lenoir, H. Lynch, J. Feunteun, P. Devilee, C. J. Cornelisse, F. H. Menko, P. A. Daly, W. Ormiston, R. McManus, C. Pye, C. M. Lewis, L. A. Cannon-Albright, J. Peto, B. A. J. Ponder, M. H. Skolnick, D. F. Easton, D. E. Goldgar, and M. R. Stratton (1994). Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science
Y. Miki, J. Swensen, D. Shattuck-Eidens, P. A. Futreal, K. Harshman, S. Tavtigian, Q. Liu, C. Cochran, L. M. Bennett, W. Ding, R. Bell, J. Rosenthal, C. Hussey, T. Tran, M. McClure, C. Frye, T. Hattier, R. Phelps, A. Haugen-Strano, H. Katcher, K. Yakumo, Z. Gholami, D. Shaffer, S. Stone, S. Bayer, C. Wray, G. Bogdan, P. Dayananth, J. Ward, P. Tonin, S. Narod, P. K. Bristow, F. H. Norris, L. Helvering, P. Morrison, P. Rosteck, M. Lai, J. C. Barrett, C. Lewis, S. Neuhausen, L. Cannon-Albright, D. Goldgar, R. Wiseman, A. Kamb, and M. H. Skolnick (1994). A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science
R. Wooster, G. Bignell, J. Lancaster, S. Swift, S. Seal, J. Mangion, N. Collins, S. Gregory, C. Gumbs, and G. Micklem (1995). Identification of the breast cancer susceptibility gene BRCA2. Nature
S. V. Tavtigian, J. Simard, J. Rommens, F. Couch, D. Shattuck-Eidens, S. Neuhausen, S. Merajver, S. Thorlacius, K. Offit, D. Stoppa-Lyonnet, C. Belanger, R. Bell, S. Berry, R. Bogden, Q. Chen, T. Davis, M. Dumont, C. Frye, T. Hattier, S. Jammulapati, T. Janecki, P. Jiang, R. Kehrer, J. F. Leblanc, J. T. Mitchell, J. McArthur-Morrison, K. Nguyen, Y. Peng, C. Samson, M. Schroeder, S. C. Snyder, L. Steele, M. Stringfellow, C. Stroup, B. Swedlund, J. Swensen, D. Teng, A. Thomas, T. Tran, M. Tranchant, J. Weaver-Feldhaus, A. K. C. Wong, H. Shizuya, J. E. Eyfjord, L. Cannon-Albright, F. Labrie, M. Skolnick, B. Weber, A. Kamb, and D. E. Goldgar (1996). The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat. Genet.
D. F. Easton, F. E. Matthews, D. Ford, A. J. Swerdlow, and J. Peto (1996). Cancer mortality in relatives of women with ovarian cancer: The OPCS Study. Office of Population Censuses and Surveys. Int. J. Cancer.
J. Peto, D. F. Easton, F. E. Matthews, D. Ford, and A. J. Swerdlow (1996). Cancer mortality in relatives of women with breast cancer: The OPCS Study. Office of Population Censuses and Surveys. Int. J. Cancer.
N. Collins, R. McManus, R. Wooster, J. Mangion, S. Seal, S. R. Lakhani, W. Ormiston, P. A. Daly, D. Ford, D. F. Easton, and M. R. Stratton (1995). Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. Oncogene
S. A. Smith, D. F. Easton, D. G. Evans, and B. A. Ponder (1992). Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nat. Genet.
P. L. Welcsh, and M. C. King (2001). BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum. Mol. Genet.
M. Montagna, P. M. Dalla, C. Menin, S. Agata, A. De Nicolo, L. Chieco-Bianchi, and E. D'Andrea (2003). Genomic rear-rangements account for more than one-third of the BRCA1 mutations in northern Italian breast/ovarian cancer families. Hum. Mol. Genet.
T. M. Smith, M. K. Lee, C. I. Szabo, N. Jerome, M. McEuen, M. Taylor, L. Hood, and M. C. King (1996). Complete genomic sequence and analysis of 117 kb of human DNA containing the gene BRCA1. Genome Res.
F. Durocher, D. Shattuck-Eidens, M. McClure, F. Labrie, M. H. Skolnick, D. E. Goldgar, and J. Simard (1996). Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations. Hum. Mol. Genet.
A. M. Dunning, M. Chiano, N. R. Smith, J. Dearden, M. Gore, S. Oakes, C. Wilson, M. Stratton, J. Peto, D. Easton, D. Clayton, and B. A. Ponder (1997). Common BRCA1 variants and susceptibility to breast and ovarian cancer in the general population. Hum. Mol. Genet.
C. S. Healey, A. M. Dunning, M. D. Teare, D. Chase, L. Parker, J. Burn, J. Chang-Claude, A. Mannermaa, V. Kataja, D. G. Huntsman, P. D. Pharoah, R. N. Luben, D. F. Easton, and B. A. Ponder (2000). A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability. Nat. Genet.
A. B. Spurdle, J. L. Hopper, X. Chen, G. S. Dite, J. Cui, M. R. McCredie, G. G. Giles, S. Ellis-Steinborner, D. J. Venter, B. Newman, M. C. Southey, and G. Chenevix-Trench (2002). The BRCA2 372 HH genotype is associated with risk of breast cancer in Australian women under age 60 years. Cancer Epidemiol. Biomarkers Prev.
J. Simard, P. Tonin, F. Durocher, K. Morgan, J. Rommens, S. Gingras, C. Samson, J. F. Leblanc, C. Bélanger, F. Dion, Q. Liu, M. Skolnick, D. Goldgar, D. Shattuck-Eidens, F. Labrie, and S. A. Narod (1994). Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nat. Genet.
R. B. Bar-Sade, A. Kruglikova, B. Modan, E. Gak, G. Hirsh-Yechezkel, L. Theodor, I. Novikov, R. Gershoni-Baruch, S. Risel, M. Z. Papa, G. Ben Baruch, and E. Friedman (1998). The 185delAG BRCA1 mutation originated before the dispersion of Jews in the diaspora and is not limited to Ashkenazim. Hum. Mol. Genet.
C. F. Xu, J. A. Chambers, H. Nicolai, M. A. Brown, Y. Hujeirat, S. Mohammed, S. Hodgson, D. P. Kelsell, N. K. Spurr, D. T. Bishop, and E. Solomon (1997). Mutations and alternative splicing of the BRCA1 gene in UK breast/ovarian cancer families. Genes Chromosomes Cancer
L. G. Mullineaux, T. M. Castellano, J. Shaw, L. Axell, M. E. Wood, S. Diab, C. Klein, M. Sitarik, A. M. Deffenbaugh, and S. L. Graw (2003). Identification of germline 185delAG BRCA1 mutations in non-Jewish Americans of Spanish ancestry from the San Luis Valley, Colorado. Cancer
D. B. Berman, J. Costalas, D. C. Schultz, G. Grana, M. Daly, and A. K. Godwin (1996). A common mutation in BRCA2 that predisposes to a variety of cancers is found in both Jewish Ashkenazi and non-Jewish individuals. Cancer Res.
F. H. Fodor, A. Weston, I. J. Bleiweiss, L. D. McCurdy, M. M. Walsh, P. I. Tartter, S. T. Brower, and C. M. Eng (1998). Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. Am. J. Hum. Genet.
M. G. FitzGerald, D. J. MacDonald, M. Krainer, I. Hoover, E. O'Neil, H. Unsal, S. Silva-Arrieto, D. M. Finkelstein, P. Beer-Romero, C. Englert, D. C. Sgroi, B. L. Smith, J. W. Younger, J. E. Garber, R. B. Duda, K. A. Mayzel, K. J. Isselbacher, S. H. Friend, and D. A. Haber (1996). Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N. Engl. J. Med.
E. Warner, W. Foulkes, P. Goodwin, W. Meschino, J. Blondal, C. Paterson, H. Ozcelik, P. Goss, D. Allingham-Hawkins, N. Hamel, L. Di Prospero, V. Contiga, C. Serruya, M. Klein, R. Moslehi, J. Honeyford, A. Liede, G. Glendon, J. S. Brunet, and S. Narod (1999). Prevalence and pene-trance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J. Natl. Cancer. Inst.
J. M. Satagopan, K. Offit, W. Foulkes, M. E. Robson, S. Wacholder, C. M. Eng, S. E. Karp, and C. B. Begg (2001). The lifetime risks of breast cancer in Ashkenazi Jewish car-riers of BRCA1 and BRCA2 mutations. Cancer Epidemiol. Biomarkers Prev.
S. Neuhausen, T. Gilewski, L. Norton, T. Tran, P. McGuire, J. Swensen, H. Hampel, P. Borgen, K. Brown, M. Skolnick, D. Shattuck-Eidens, S. Jhanwar, D. Goldgar, and K. Offit (1996). Recurrent BRCA2 6174delT mutations in Ashke-nazi Jewish women affected by breast cancer. Nat. Genet.
K. Offit, T. Gilewski, P. McGuire, A. Schluger, H. Ham-pel, K. Brown, J. Swensen, S. Neuhausen, M. Skolnick, L. Norton, and D. Goldgar (1996). Germline BRCA1 185de-lAG mutations in Jewish women with breast cancer. Lancet
R. Moslehi, W. Chu, B. Karlan, D. Fishman, H. Risch, A. Fields, D. Smotkin, Y. Ben David, J. Rosenblatt, D. Russo, P. Schwartz, N. Tung, E. Warner, B. Rosen, J. Friedman, J. S. Brunet, and S. A. Narod (2000). BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am. J. Hum. Genet.
D. Abeliovich, L. Kaduri, I. Lerer, N. Weinberg, G. Amir, M. Sagi, J. Zlotogora, N. Heching, and T. Peretz (1997). The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am. J. Hum. Genet.
J. Gudmundsson, G. Johannesdottir, A. Arason, J. T. Bergthorsson, S. Ingvarsson, V. Egilsson, and R. B. Barkardottir (1996). Frequent occurrence of BRCA2 linkage in Icelandic breast cancer families and segregation of a common BRCA2 haplotype. Am. J. Hum. Genet.
S. Thorlacius, G. Olafsdottir, L. Tryggvadottir, S. Neuhausen, J. G. Jonasson, S. V. Tavtigian, H. Tulinius, H. M. Ogmundsdottir, and J. E. Eyfjord (1996). A single BRCA2 mutation in male and female breast cancer families from Ice-land with varied cancer phenotypes. Nat. Genet.
G. Johannesdottir, J. Gudmundsson, J. T. Bergthorsson, A. Arason, B. A. Agnarsson, G. Eiriksdottir, O. T. Johannsson, A. Borg, S. Ingvarsson, D. F. Easton, V. Egilsson, and R. B. Barkardottir (1996). High prevalence of the 999del5 mutation in Icelandic breast and ovarian cancer patients. Cancer Res.
S. Thorlacius, S. Sigurdsson, H. Bjarnadottir, G. Olafsdottir, J. G. Jonasson, L. Tryggvadottir, H. Tulinius, and J. E. Eyfjord (1997) Study of a single BRCA2 mutation with high carrier frequency in a small population. Am. J. Hum. Genet.
E. Friedman, B. R. Bar-Sade, A. Kruglikova, S. Risel, E. Levy-Lahad, D. Halle, E. Bar-On, R. Gershoni-Baruch, E. Dagan, I. Kepten, T. Peretz, I. Lerer, N. Wienberg, A. Shushan, and A. D. Abeliovich (1998). Double heterozy-gotes for the Ashkenazi founder mutations in BRCA1 and BRCA2 genes. Am. J. Hum. Genet.
F. Connor, D. Bertwistle, P. J. Mee, G. M. Ross, S. Swift, E. Grigorieva, V. L. Tybulewicz, and A. Ashworth (1997). Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutation. Nat. Genet.
L. C. Gowen, B. L. Johnson, A. M. Latour, K. K. Sulik, and B. H. Koller (1996). Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities. Nat. Genet.
M. Boyd, F. Harris, R. McFarlane, H. R. Davidson, and D. M. Black (1995). A human BRCA1 gene knockout. Nature
B. Kuschel, S. A. Gayther, D. F. Easton, B. A. Ponder, and P. D. Pharoah (2001). Apparent human BRCA1 knockout caused by mispriming during polymerase chain reaction: implications for genetic testing. Genes Chromosomes Cancer
N. G. Howlett, T. Taniguchi, S. Olson, B. Cox, Q. Waisfisz, C. Die-Smulders, N. Persky, M. Grompe, H. Joenje, G. Pals, H. Ikeda, E. A. Fox, and A. D. D'Andrea (2002). Biallelic inactivation of BRCA2 in Fanconi anemia. Science
A. Antoniou, P. D. Pharoah, S. Narod, H. A. Risch, J. E. Eyfjord, J. L. Hopper, N. Loman, H. Olsson, O. Johannsson, A. Borg, B. Pasini, P. Radice, S. Manoukian, D. M. Eccles, N. Tang, E. Olah, H. Anton-Culver, E. Warner, J. Lubinski, J. Gronwald, B. Gorski, H. Tulinius, S. Thorlacius, H. Eerola, H. Nevanlinna, K. Syrjakoski, O. P. Kallioniemi, D. Thompson, C. Evans, J. Peto, F. Lalloo, D. G. Evans, and D. F. Easton (2003). Average risks of breast and ovarian can-cer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. Am. J. Hum. Genet.
D. Ford, D. F. Easton, M. Stratton, S. Narod, D. Goldgar, P. Devilee, D. T. Bishop, B. Weber, G. Lenoir, J. Chang-Claude, H. Sobol, M. D. Teare, J. Struewing, A. Arason, S. Scherneck, J. Peto, T. R. Rebbeck, P. Tonin, S. Neuhausen, R. Barkardottir, J. Eyfjord, H. Lynch, B. A. Ponder, S. A. Gayther, M. Zelada-Hedman, and The Breast Cancer Linkage Consortium (1998). Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am. J. Hum. Genet.
D. F. Easton, D. Ford, D. T. Bishop, and Breast Cancer Linkage Consortium (1995). Breast and ovarian cancer incidence in BRCA1-mutation carriers. Am. J. Hum. Genet.
M. C. King, J. H. Marks, and J. B. Mandell (2003). Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science
S. A. Gayther, W. Warren, S. Mazoyer, P. A. Russell, P. A. Harrington, M. Chiano, S. Seal, R. Hamoudi, E. J. van Rensburg, A. M. Dunning, R. Love, G. Evans, D. Easton, D. Clayton, M. R. Stratton, and B. A. J. Ponder (1995). Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype- phenotype correlation. Nat. Genet.
D. Thompson, and D. Easton (2002). Breast Cancer Linkage Consortium. Variation in BRCA1 cancer risks by mutation position. Cancer Epidemiol. Biomarkers Prev.
D. Thompson, and D. Easton (2001). Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am. J. Hum. Genet.
S. A. Gayther, J. Mangion, P. Russell, S. Seal, R. Barfoot, B. A. Ponder, M. R. Stratton, and D. Easton (1997). Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat. Genet.
J. Peto, N. Collins, R. Barfoot, S. Seal, W. Warren, N. Rahman, D. F. Easton, C. Evans, J. Deacon, and M. R. Stratton (1999). Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J. Natl. Cancer Inst.
Anglian Breast Cancer Study Group (2000). Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br.J.Cancer
M. Krainer, S. Silva-Arrieta, M. G. FitzGerald, A. Shimada, C. Ishioka, R. Kanamaru, D. J. MacDonald, H. Unsal, D. M. Finkelstein, A. Bowcock, K. J. Isselbacher, and D. A. Haber (1997). Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer. N. Engl. J. Med.
D. M. Eccles, P. Englefield, M. A. Soulby, and I. G. Campbell (1998). BRCA1 mutations in southern England. Br. J. Cancer
K. E. Malone, J. R. Daling, J. D. Thompson, C. A. O'Brien, L. V. Francisco, and E. A. Ostrander (1998). BRCA1 muta-tions and breast cancer in the general population: Analyses in women before age 35 years and in women before age 45 years with first-degree family history. JAMA
B. Newman, H. Mu, L. M. Butler, R. C. Millikan, P. G. Moorman, and M. C. King (1998). Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA
J. L. Hopper, M. C. Southey, G. S. Dite, D. J. Jolley, G. G. Giles, M. R. McCredie, D. F. Easton, D. J. Venter, and Australian Breast Cancer Family Study (1999). Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating muta-tions in BRCA1 and BRCA2. Cancer Epidemiol. Biomarkers Prev.
N. Loman, O. Johannsson, U. Kristoffersson, H. Olsson, and A. Borg (2001). Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer. J. Natl. Cancer Inst.
D. Ford, D. F. Easton, and J. Peto (1995). Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am. J. Hum. Genet.
A. C. Antoniou, P. D. Pharoah, G. McMullan, N. E. Day, M. R. Stratton, J. Peto, B. J. Ponder, and D. F. Easton (2002). A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br. J. Cancer
A. C. Antoniou, S. A. Gayther, J. F. Stratton, B. A. Ponder, and D. F. Easton (2000). Risk models for familial ovarian and breast cancer. Genet. Epidemiol.
F. J. Couch, L. M. Farid, M. L. Deshano, S. V. Tavtigian, K. Calzone, L. Campeau, Y. Peng, B. Bogden, Q. Chen, S. Neuhausen, D. Shattuck-Eidens, A. K. Godwin, M. Daly, D. M. Radford, S. Sedlacek, J. Rommens, J. Simard, J. Garber, S. Merajver, and B. L. Weber (1996). BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat. Genet.
L. S. Friedman, S. A. Gayther, T. Kurosaki, D. Gordon, B. Noble, G. Casey, B. A. Ponder, and H. Anton-Culver (1997). Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am. J. Hum. Genet.
K. Haraldsson, N. Loman, Q. X. Zhang, O. Johannsson, H. Olsson, and A. Borg (1998). BRCA2 germ-line mutations are frequent in male breast cancer patients without a family history of the disease. Cancer Res.
E. Kwiatkowska, M. Teresiak, K. M. Lamperska, A. Karczewska, D. Breborowicz, M. Stawicka, D. Godlewski, W. J. Krzyzosiak, and A. Mackiewicz (2001). BRCA2 germline mutations in male breast cancer patients in the Polish population. Hum. Mutat.
E. Mavraki, I. C. Gray, D. T. Bishop, and N. K. Spurr (1997). Germline BRCA2 mutations in men with breast cancer. Br. J. Cancer
S. R. Lakhani, J. Jacquemier, J. P. Sloane, B. A. Gusterson, T. J. Anderson, M. J. van de Vijver, L. M. Farid, D. Venter, A. Antoniou, A. Storfer-Isser, E. Smyth, C. M. Steel, N. Haites, R. J. Scott, D. Goldgar, S. Neuhausen, P. A. Daly, W. Ormiston, R. McManus, S. Scherneck, B. A. Ponder, D. Ford, J. Peto, D. Stoppa-Lyonnet, Y. J. Bignon, J. P. Struewing, N. K. Spurr, D. T. Bishop, J. G. M. Klijn, P. Devilee, C. Cornelisse, C. Lasset, G. Lenoir, R. B. Barkardottir, V. Egilsson, U. Hamann, J. Chang-Claude, H. Sobol, B. Weber, M. R. Stratton, and D. F. Easton (1998). Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J. Natl. Cancer Inst.
Breast Cancer Linkage Consortium (1997). Pathology of familial breast cancer: Differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet
J. N. Marcus, P. Watson, D. L. Page, S. A. Narod, G. M. Lenoir, P. Tonin, L. Linder-Stephenson, G. Salerno, T. A. Conway, and H. T. Lynch (1996). Hereditary breast cancer: Pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer
O. T. Johannsson, I. Idvall, C. Anderson, A. Borg, R. B. Barkardottir, V. Egilsson, and H. Olsson (1997). Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur. J. Cancer
U. Hamann, and H. P. Sinn (2000). Survival and tumor characteristics of German hereditary breast cancer patients. Breast Cancer Res. Treat.
D. Stoppa-Lyonnet, Y. Ansquer, H. Dreyfus, C. Gautier, M. Gauthier-Villars, E. Bourstyn, K. B. Clough, H. Magdelenat, P. Pouillart, A. Vincent-Salomon, A. Fourquet, and B. Asselain (2000). Familial invasive breast cancers: Worse outcome related to BRCA1 mutations. J. Clin. Oncol.
D. Turchetti, L. Cortesi, M. Federico, C. Bertoni, L. Mangone, S. Ferrari, and V. Silingardi (2000). BRCA1 mutations and clinicopathological features in a sample of Italian women with early-onset breast cancer. Eur. J. Cancer
M. Robson, T. Gilewski, B. Haas, D. Levin, P. Borgen, P. Rajan, Y. Hirschaut, P. Pressman, P. P. Rosen, M. L. Lesser, L. Norton, and K. Offit (1998). BRCA-associated breast cancer in young women. J. Clin. Oncol.
K. A. Phillips, K. Nichol, H. Ozcelik, J. Knight, S. J. Done, P. J. Goodwin, and I. L. Andrulis (1999). Frequency of p53 mu-tations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations. J. Natl. Cancer Inst.
S. R. Lakhani, M. J. van de Vijver, J. Jacquemier, T. J. Anderson, P. P. Osin, L. McGuffog, and D. F. Easton (2002). The pathology of familial breast cancer: Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J. Clin. Oncol.
S. A. Narod, J. S. Brunet, P. Ghadirian, M. Robson, K. Heimdal, S. L. Neuhausen, D. Stoppa-Lyonnet, C. Lerman, B. Pasini, R. P. de los, B. Weber, H. Lynch, and Hereditary Breast Cancer Clinical Study Group (2000). Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: A case-control study. Lancet
C. M. Perou, T. Sorlie, M. B. Eisen, van de RM, S. S. Jeffrey, C. A. Rees, J. R. Pollack, D. T. Ross, H. Johnsen, L. A. Akslen, O. Fluge, A. Pergamenschikov, C. Williams, S. X. Zhu, P. E. Lonning, A. L. Borresen-Dale, P. O. Brown, and D. Botstein (2000). Molecular portraits of human breast tumours. Nature
W. D. Foulkes, I. M. Stefansson, P. O. Chappuis, L. R. Begin, J. R. Goffin, N. Wong, M. Trudel, and L. A. Akslen (2003). Germline BRCA1 mutations and a basal epithelial pheno-type in breast cancer. J. Natl. Cancer Inst.
H. Eerola, P. Vahteristo, L. Sarantaus, P. Kyyronen, S. Pyrhonen, C. Blomqvist, E. Pukkala, H. Nevanlinna, and R. Sankila (2001). Survival of breast cancer patients in BRCA1, BRCA2, and non-BRCA1/2 breast cancer families: A rela-tive survival analysis from Finland. Int. J. Cancer
A. A. Jazaeri, C. J. Yee, C. Sotiriou, K. R. Brantley, J. Boyd, and E. T. Liu (2002). Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J. Natl. Cancer Inst.
D. Thompson, and D. F. Easton (2002). Cancer incidence in BRCA1 mutation carriers. J. Natl. Cancer Inst.
Breast Cancer Linkage Consortium (1999). Cancer risks in BRCA2 mutation carriers. J. Natl. Cancer Inst.
S. Sigurdsson, S. Thorlacius, J. Tomasson, L. Tryggvadottir, K. Benediktsdottir, J. E. Eyfjord, and E. Jonsson (1997). BRCA2 mutation in Icelandic prostate cancer patients. J. Mol. Med.
S. M. Edwards, Z. Kote-Jarai, J. Meitz, R. Hamoudi, Q. Hope, P. Osin, R. Jackson, C. Southgate, R. Singh, A. Falconer, D. P. Dearnaley, A. Ardern-Jones, A. Murkin, A. Dowe, J. Kelly, S. Williams, R. Oram, M. Stevens, D. M. Teare, B. A. Ponder, S. A. Gayther, D. F. Easton, and R. A. Eeles (2003). Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am. J. Hum. Genet.
S. A. Gayther, K. A. de Foy, P. Harrington, P. Pharoah, W. D. Dunsmuir, S. M. Edwards, C. Gillett, A. Ardern-Jones, D. P. Dearnaley, D. F. Easton, D. Ford, R. J. Shearer, R. S. Kirby, A. L. Dowe, J. Kelly, M. R. Stratton, B. A. Ponder, D. Barnes, R. A. Eeles, and The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators (2000). The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. Cancer Res.
A. Vazina, J. Baniel, Y. Yaacobi, A. Shtriker, D. Engelstein, I. Leibovitz, M. Zehavi, A. A. Sidi, Y. Ramon, T. Tischler, P. M. Livne, and E. Friedman (2000). The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel. Br. J. Cancer
F. Clavel-Chapelon, E3N-EPIC Group (2002). Differential effects of reproductive factors on the risk of pre-and post-menopausal breast cancer. Results from a large cohort of French women. Br. J. Cancer
A. S. Whittemore, R. Harris, and J. Itnyre (1992). Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case-control studies. II: Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am. J. Epidemiol.
L. Tryggvadottir, E. J. Olafsdottir, S. Gudlaugsdottir, S. Thorlacius, J. G. Jonasson, H. Tulinius, and J. E. Eyfjord (2003). BRCA2 mutation carriers, reproductive factors and breast cancer risk. Breast Cancer Res.
B. Modan, P. Hartge, G. Hirsh-Yechezkel, A. Chetrit, F. Lubin, U. Beller, G. Ben Baruch, A. Fishman, J. Menczer, S. M. Ebbers, M. A. Tucker, S. Wacholder, J. P. Struewing, E. Friedman, and B. Piura (2001). Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncar-riers of a BRCA1 or BRCA2 mutation. N. Engl. J. Med.
T. R. Rebbeck, Y. Wang, P. W. Kantoff, K. Krithivas, S. L. Neuhausen, A. K. Godwin, M. B. Daly, S. A. Narod, J. S. Brunet, D. Vesprini, J. E. Garber, H. T. Lynch, B. L. Weber, and M. Brown (2001). Modification of BRCA1-and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history. Cancer Res.
S. A. Narod, M. P. Dube, J. Klijn, J. Lubinski, H. T. Lynch, P. Ghadirian, D. Provencher, K. Heimdal, P. Moller, M. Robson, K. Offit, C. Isaacs, B. Weber, E. Friedman, R. Gershoni-Baruch, G. Rennert, B. Pasini, T. Wagner, M. Daly, J. E. Garber, S. L. Neuhausen, P. Ainsworth, H. Olsson, G. Evans, M. Osborne, F. Couch, W. D. Foulkes, E. Warner, C. Kim-Sing, O. Olopade, N. Tung, H. M. Saal, J. Weitzel, S. Merajver, M. Gauthier-Villars, H. Jernstrom, P. Sun, and J. S. Brunet (2002). Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J. Natl. Cancer Inst.
T. R. Rebbeck, A. M. Levin, A. Eisen, C. Snyder, P. Watson, L. Cannon-Albright, C. Isaacs, O. Olopade, J. E. Garber, A. K. Godwin, M. B. Daly, S. A. Narod, S. L. Neuhausen, H. T. Lynch, and B. L. Weber (1999). Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J. Natl. Cancer Inst.
T. R. Rebbeck, P. W. Kantoff, K. Krithivas, S. Neuhausen, M. A. Blackwood, A. K. Godwin, M. B. Daly, S. A. Narod, J. E. Garber, H. T. Lynch, B. L. Weber, and M. Brown (1999). Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. Am. J. Hum. Genet.
L. Kadouri, D. F. Easton, S. Edwards, A. Hubert, Z. Kote-Jarai, B. Glaser, F. Durocher, D. Abeliovich, T. Peretz, and R. A. Eeles (2001). CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and noncarriers. Br. J. Cancer
L. Kadouri, Z. Kote-Jarai, D. F. Easton, A. Hubert, R. Hamoudi, B. Glaser, D. Abeliovich, T. Peretz, and R. A. Eeles (2004). Polyglutamine repeat length in the AIB1 gene modifies breast cancer susceptibility in BRCA1 carriers. Int. J. Cancer
M. Redston, K. L. Nathanson, Z. Q. Yuan, S. L. Neuhausen, J. Satagopan, N. Wong, D. Yang, D. Nafa, J. Abrahamson, H. Ozcelik, D. Antin-Ozerkis, I. Andrulis, M. Daly, L. Pinsky, D. Schrag, S. Gallinger, M. Kaback, M. C. King, T. Woodage, L. C. Brody, A. Godwin, E. Warner, B. Weber, W. Foulkes, and K. Offit (1998). The APCI1307K allele and breast cancer risk. Nat. Genet.
E. Levy-Lahad, A. Lahad, S. Eisenberg, E. Dagan, T. Paperna, L. Kasinetz, R. Catane, B. Kaufman, U. Beller, P. Renbaum, and R. Gershoni-Baruch (2001). A single nu-cleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers. Proc. Natl. Acad. Sci. U. S. A.
W. W. Wang, A. B. Spurdle, P. Kolachana, B. Bove, B. Modan, S. M. Ebbers, G. Suthers, M. A. Tucker, D. J. Kaufman, M. M. Doody, R. E. Tarone, M. Daly, H. Levavi, H. Pierce, A. Chetrit, G. H. Yechezkel, G. Chenevix-Trench, K. Offit, A. K. Godwin, and J. P. Struewing (2001). A single nucleotide polymorphism in the 5untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers. Cancer Epidemiol. Biomarkers Prev.
A. Jakubowska, S. A. Narod, D. E. Goldgar, M. Mierzejewski, B. Masojc, K. Nej, J. Huzarska, T. Byrski, B. Gorski, and J. Lubinski (2003). Breast cancer risk reduction associated with the RAD51 polymorphism among carriers of the BRCA1 5382insC mutation in Poland. Cancer Epidemiol. Biomarkers Prev.
D. W. Bell, J. M. Varley, T. E. Szydlo, D. H. Kang, D. C. Wahrer, K. E. Shannon, M. Lubratovich, S. J. Verselis, K. J. Isselbacher, J. F. Fraumeni, J. M. Birch, F. P. Li, J. E. Garber, and D. A. Haber (1999). Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science
P. Vahteristo, A. Tamminen, P. Karvinen, H. Eerola, C. Eklund, L. A. Aaltonen, C. Blomqvist, K. Aittomaki, and H. Nevanlinna (2001). p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: Further evidence of CHK2 in inherited cancer predisposition. Cancer Res.
H. Meijers-Heijboer. (2002). CHK2 1100delC is a low pen-etrance familial breast cancer susceptibility allele that does not elevate breast cancer in BRCA1/2 mutation carriers. Nat. Genet.
P. Vahteristo, J. Bartkova, H. Eerola, K. Syrjakoski, S. Ojala, O. Kilpivaara, A. Tamminen, J. Kononen, K. Aittomaki, P. Heikkila, K. Holli, C. Blomqvist, J. Bartek, O. P. Kallioniemi, and H. Nevanlinna (2002). A CHEK2 genetic variant con-tributing to a substantial fraction of familial breast cancer. Am. J. Hum. Genet.
CHEK2 Breast Cancer Case-Control Consortium (2004). CHEK2 1100delC and susceptibility to breast cancer: A collaborative analysis involving 10,860 breast cancer cases and 9065 controls from 10 studies. Am. J. Hum. Genet.
B. Kuschel, A. Auranen, C. S. Gregory, N. E. Day, D. F. Easton, B. A. Ponder, A. M. Dunning, and P. D. Pharoah (2003). Common polymorphisms in checkpoint kinase 2 are not associated with breast cancer risk. Cancer Epidemiol. Biomarkers Prev.
M. Schutte, S. Seal, R. Barfoot, H. Meijers-Heijboer, M. Wasielewski, D. G. Evans, D. Eccles, C. Meijers, F. Lohman, J. Klijn, O. A. van den, P. A. Futreal, K. L. Nathanson, B. L. Weber, D. F. Easton, M. R. Stratton, and N. Rahman (2003). Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility. Am. J. Hum. Genet.
D. F. Easton (1994). Cancer risks in A-T heterozygotes. Int. J. Radiat Biol.
M. G. FitzGerald, J. M. Bean, S. R. Hegde, H. Unsal, D. J. MacDonald, D. P. Harkin, D. M. Finkelstein, K. J. Isselbacher, and D. A. Haber (1997). Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat. Genet.
T. Stankovic, A. M. Kidd, A. Sutcliffe, G. M. McGuire, P. Robinson, P. Weber, T. Bedenham, A. R. Bradwell, D. F. Easton, G. G. Lennox, N. Haites, P. J. Byrd, and A. M. Taylor (1998). ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: Expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer. Am. J. Hum. Genet.
Y. R. Thorstenson, A. Roxas, R. Kroiss, M. A. Jenkins, K. M. Yu, T. Bachrich, D. Muhr, T. L. Wayne, G. Chu, R. W. Davis, T. M. Wagner, and P. J. Oefner (2003). Contributions of ATM mutations to familial breast and ovarian cancer. Cancer Res.
G. Chenevix-Trench, A. B. Spurdle, M. Gatei, H. Kelly, A. Marsh, X. Chen, K. Donn, M. Cummings, D. Nyholt, M. A. Jenkins, C. Scott, G. M. Pupo, T. Dork, R. Bendix, J. Kirk, K. Tucker, M. R. McCredie, J. L. Hopper, J. Sambrook, G. J. Mann, and K. K. Khanna (2002). Dominant negative ATM mutations in breast cancer families. J. Natl. Cancer Inst.
C. I. Szabo, M. Schutte, A. Broeks, J. Houwing-Duistermaat, Y. R. Thorstenson, F. Durocher, R. A. Oldenburg, M. Wasielewski, F. Odefrey, D. Thompson, A. N. floore, J. Kraan, J. Klijn, A. M. van den Ouweland, the BRCA-X Consortium, CFRBCS, INHERIT BRCAs, T. M. Wagner, P. Devilee, J. Simard, L. J. van 't Veer, D. Goldgar, and H. Meijers-Heijboer (2004). Are ATM mutations 7271T >G and IVS10-6T >G really high-risk breast cancer-susceptibility alleles? Cancer Res.
A. M. Dunning, M. Dowsett, C. S. Healey, L. Tee, R. N. Luben, E. Folkerd, K. L. Novik, L. Kelemen, S. Ogata, P. D. Pharoah, D. F. Easton, N. E. Day, and B. A. Ponder (2004). Polymorphisms associated with circulating sex hor-mone levels in postmenopausal women. J. Natl. Cancer Inst.
D. F. Easton (1999). How many more breast cancer pre-disposition genes are there? Breast Cancer Res.
A. C. Antoniou, P. D. Pharoah, G. McMullan, N. E. Day, B. A. Ponder, and D. Easton (2001). Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study. Genet. Epidemiol.
P. Huusko, S. H. Juo, E. Gillanders, L. Sarantaus, T. Kainu, P. Vahteristo, M. Allinen, M. Jones, K. Rapakko, H. Eerola, C. Markey, P. Vehmanen, D. Gildea, D. Freas-Lutz, C. Blomqvist, J. Leisti, G. Blanco, U. Puistola, J. Trent, J. Bailey-Wilson, R. Winqvist, H. Nevanlinna, and O. P. Kallioniemi (2004). Genome-wide scanning for linkage in Finnish breast cancer families. Eur. J. Hum. Genet.
T. Kainu, S. H. Juo, R. Desper, A. A. Schaffer, E. Gillanders, E. Rozenblum, D. Freas-Lutz, D. Weaver, D. Stephan, J. Bailey-Wilson, O. P. Kallioniemi, M. Tirkkonen, K. Syrjakoski, T. Kuukasjarvi, P. Koivisto, R. Karhu, K. Holli, A. Arason, G. Johannesdottir, J. T. Bergthorsson, H. Johannsdottir, V. Egilsson, R. B. Barkardottir, O. Johannsson, K. Haraldsson, T. Sandberg, E. Holmberg, H. Gronberg, H. Olsson, A. Borg, P. Vehmanen, H. Eerola, P. Heikkila, S. Pyrhonen, and H. Nevanlinna (2000). Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus. Proc. Natl. Acad. Sci. U. S. A.
N. Rahman, M. D. Teare, S. Seal, H. Renard, J. Mangion, C. Cour, D. Thompson, Y. Shugart, D. Eccles, P. Devilee, H. Meijers, K. L. Nathanson, S. L. Neuhausen, B. Weber, J. Chang-Claude, D. F. Easton, D. Goldgar, and M. R. Stratton (2000). Absence of evidence for a familial breast cancer susceptibility gene at chromosome 8p12-p22. Oncogene
S. Seitz, K. Rohde, E. Bender, A. Nothnagel, K. Kolble, P. M. Schlag, and S. Scherneck (1997). Strong indication for a breast cancer susceptibility gene on chromosome 8p12-p22: Linkage analysis in German breast cancer families. Oncogene
D. Thompson, C. I. Szabo, J. Mangion, R. A. Oldenburg, F. Odefrey, S. Seal, R. Barfoot, K. Kroeze-Jansema, D. Teare, N. Rahman, H. Renard, C. KConFab, G. Mann, J. L. Hopper, S. S. Buys, I. L. Andrulis, R. Senie, M. B. Daly, D. West, E. A. Ostrander, K. Offit, T. Peretz, A. Osorio, J. Benitez, K. L. Nathanson, O. M. Sinilnikova, E. Olah, Y. J. Bignon, P. Ruiz, M. D. Badzioch, H. F. Vasen, A. P. Futreal, C. M. Phelan, S. A. Narod, H. T. Lynch, B. A. Ponder, R. A. Eeles, H. Meijers-Heijboer, D. Stoppa-Lyonnet, F. J. Couch, D. M. Eccles, D. G. Evans, J. Chang-Claude, G. Lenoir, B. L. Weber, P. Devilee, D. F. Easton, D. E. Goldgar, and M. R. Stratton (2002). Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium. Proc. Natl. Acad. Sci. U. S. A.
A. M. Dunning, C. S. Healey, P. D. Pharoah, M. D. Teare, B. A. Ponder, and D. F. Easton (1999). A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol. Biomarkers Prev.
H. Meijers-Heijboer, J. Wijnen, H. Vasen, M. Wasielewski, A. Wagner, A. Hollestelle, F. Elstrodt, B. R. van den, A. de Snoo, G. T. Fat, C. Brekelmans, S. Jagmohan, P. Franken, P. Verkuijlen, O. A. van den, P. Chapman, C. Tops, G. Moslein, J. Burn, H. Lynch, J. Klijn, R. Fodde, and M. Schutte (2003). The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype. Am. J. Hum. Genet.
F. Lalloo, J. Varley, D. Ellis, A. Moran, L. O'Dair, P. Pharoah, and D. G. Evans (2003). Prediction of pathogenic mutations in patients with early-onset breast cancer by family history. Lancet
A. Chompret, L. Brugieres, M. Ronsin, M. Gardes, F. Dessarps-Freichey, A. Abel, D. Hua, L. Ligot, M. G. Dondon, B. Bressac-de Paillerets, T. Frebourg, J. Lemerle, C. Bonaiti-Pellie, and J. Feunteun (2000). P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br. J. Cancer
S. Ball, M. Arolker, and A. D. Purushotham (2001). Breast cancer, Cowden disease and PTEN-MATCHS syndrome. Eur. J. Surg. Oncol.
D. M. Parkin, S. L. Whelan, J. Ferlay, L. Teppo, and D. B. Thomas (2002). Cancer Incidence in Five Continents. IARC, Lyon, France.